|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Navidea Biopharmaceuticals
| | | Phone: | (614) 793-7500 | Year Established: | 1983 | Ticker: | NAVB | Exchange: | NYSE | Main Contact: | Thomas Tulip, Ph.D., Executive VP & CBO | | Other Contacts: | Anton Gueth, Chairman Michael Tomblyn, M.D., M.S., Executive Medical Director Thomas J. Klima, Executive VP & CCO Rodger A. Brown, Senior VP, Global Regulatory Operations & Quality Assurance Michael M. Goldberg, M.D., President & CEO Brent L. Larson, Senior VP & CFO Frederick O. Cope, Ph.D., F.A.C.N., C.N.S., Senior VP & CSO
| | Company Description | Navidea Biopharmaceuticals (formerly Neoprobe), a leader in precision diagnostics, is a biopharmaceutical company developing novel radiopharmaceutical imaging agents to help identify the presence and status of disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts.
Navidea Biopharmaceuticals was founded as Neoprobe Corporation in 1983. With the sale of the neoprobe®GDS medical device business in 2011, Navidea Biopharmaceuticals was born. | |
|
|
|
|
|